Skip to main content
. 2019 Sep 21;23(11):7632–7640. doi: 10.1111/jcmm.14636

Figure 5.

Figure 5

Raf‐1/p70S6K signalling maintains NSCLC tumorigenicity in vivo. A, Tumour growth curve of tumours generated from H1299 (left) and H460 (right) cells with negative control (NC), Raf‐1 knock‐down (shRaf‐1) and p70S6K overexpression following Raf‐1 knock‐down (shRaf‐1 + OE‐p70S6K). B, Comparison of tumour weights between negative control (NC) and Raf‐1 knock‐down (shRaf‐1) and between Raf‐1 knock‐down (shRaf‐1) and p70S6K overexpression following Raf‐1 knock‐down (shRaf‐1 + OE‐p70S6K) groups; *P < .05. C, Western blot analysis confirming the knock‐down status of Raf‐1 and the overexpression status of p70S6K in tumour tissues. D, Immunohistochemical staining with Ki‐67 (left) showing NSCLC tumour cell proliferation in each group (×400). Large brown Ki‐67 staining (arrow) indicates proliferating cells. TUNEL staining (middle and right) demonstrating apoptotic cells in each group (×400). Positive cells are indicated by arrows